Stockreport

Spyre Therapeutics doses first subjects in Phase I IBD treatment trial [Yahoo! Finance]

Spyre Therapeutics, Inc.  (SYRE) 
PDF The placebo-controlled, double-blind trial is set to enrol approximately 48 healthy adult participants. It will have four single-ascending dose (SAD) and two multi-asce [Read more]